Study reveals that Ozempic reduces depression, anxiety and addiction... and nobody knows exactly why - critical summary review

Imagine you take your car to the mechanic for an oil change... and when you get it back, you discover the engine sounds better, the air conditioning blows colder and the windows stopped fogging up. Nobody can explain why. But the results are right there.

That is more or less what is happening with semaglutide... the active ingredient in Ozempic, Wegovy and Rybelsus. A drug created for type two diabetes and weight loss that, apparently, is tapping into something much deeper in the human body... mental health.

In March of two thousand and twenty six, The Lancet Psychiatry published the largest study ever conducted on the relationship between this class of medications and psychiatric disorders. And the numbers are striking.

Researchers from the University of Eastern Finland, the Karolinska Institute in Stockholm and Griffith University in Australia analyzed national medical records from Sweden between two thousand and nine and two thousand and twenty two. Nearly one hundred thousand people were included in the sample. More than twenty thousand of them had used medications from the GLP one class... the so called glucagon like peptide one receptor agonists. That long name hides a relatively simple mechanism... these are substances that mimic a hormone the gut itself produces after we eat.

And what did the researchers find?

During the periods when patients were using semaglutide, psychiatric hospitalizations and sick leave for mental health reasons dropped forty two percent compared to periods without the medication. Depression fell forty four percent. Anxiety disorders decreased thirty eight percent. And perhaps the most surprising figure... substance use problems, including alcohol and drugs, dropped forty seven percent. On top of that, the study identified a reduction in the risk of suicidal behavior.

An important clarification is needed here. These numbers do not mean that Ozempic cures depression or anxiety. The study is observational. It shows association, not causation. In other words... it tells us that these things happen together, but it does not prove that one causes the other. It is the difference between noticing that people carrying umbrellas tend to encounter rainy days... and concluding that the umbrella causes the rain.

That said... when the association shows up in a sample of nearly one hundred thousand people, over thirteen years, using data from a robust healthcare system like Sweden's, science pays attention.

The hungry brain hypothesis

What leads a diabetes drug to have effects on depression, anxiety and addiction?

The most widely accepted answer among researchers points to something called the brain's reward system. Think of it as an electrical circuit in the brain that lights up every time something feels pleasurable... eating something delicious, hearing a song you love, receiving a compliment. This circuit runs primarily on dopamine, a neurotransmitter that signals satisfaction.

At the center of this system is a region called the ventral tegmental area, which scientists abbreviate as VTA. From there, connections branch out to the nucleus accumbens, which translates the dopamine signal into motivation... and to the prefrontal cortex, which helps decide whether it is worth pursuing that reward again.

It turns out that GLP one receptors do not exist only in the pancreas and the gut. They are scattered throughout precisely these brain regions... the VTA, the nucleus accumbens, the amygdala, the hippocampus. And semaglutide, unlike older versions such as liraglutide, penetrates the central nervous system far more easily. It literally reaches the heart of the reward circuit.

Preclinical studies in rodents have already shown that GLP one agonists modulate dopamine levels, reduce the seeking of cocaine, amphetamine, alcohol and nicotine, and alter the brain's response to pleasurable stimuli. A study published in the journal Neuroscience Applied showed that semaglutide does not change the brain's reaction when it anticipates pleasure... but it increases the dopamine signal at the moment pleasure actually arrives. In plain terms... the drug does not seem to affect desire, but it intensifies satisfaction with what is already there.

The implications are enormous. One of the strongest theories about depression holds that it involves a defect in precisely this circuit... anhedonia, the inability to feel pleasure. If semaglutide truly improves reward signaling, it would be targeting one of the deepest mechanisms of the illness. Not the symptoms. The engine.

But there is an alternative pathway that also helps explain these numbers. People who lose significant weight, who bring their blood sugar under control and who feel more physical energy naturally sleep better, move more and develop a different relationship with their own bodies. All of this improves mood. It is possible that part of the mental health effect comes simply from being healthier.

The Swedish researchers acknowledge that separating these two pathways... a direct effect on the brain versus an indirect improvement through the body... is the great challenge for future studies.

The other side of the coin

Before rushing to the pharmacy, it is necessary to look at the full picture.

First... the Swedish study followed people who already had a diagnosis of depression or anxiety and who also had type two diabetes or obesity. These were not healthy volunteers looking to shed a few pounds for summer. The population studied is specific, and the results do not automatically apply to everyone.

Second... a pharmacovigilance study published in two thousand and twenty five in the journal Clinical Nutrition, using data from the World Health Organization's global VigiBase, found signals pointing in the opposite direction. The analysis of more than two million adverse reaction reports identified that semaglutide was associated with an increased risk of reports of depressed mood, anxiety and suicidal ideation compared to other antidiabetic medications. The same study identified concerning signals for eating disorders across all three classes of GLP one agonists analyzed.

How is it possible that a drug reduces depression in one study and increases reports of depression in another? The answer lies in the type of evidence. The Swedish study followed the same individuals over time, comparing periods with and without the medication. The pharmacovigilance data, on the other hand, comes from spontaneous reports... any doctor or patient can report an adverse effect, but not every adverse effect gets reported. The two types of study capture different aspects of the same reality.

Third... the everyday side effects are real and relevant. Nausea is the most common, affecting roughly twenty percent of users in clinical trials. Vomiting, diarrhea and abdominal pain appear frequently. Rare but serious cases include pancreatitis, gallbladder problems and kidney damage. In rodent tests, semaglutide was associated with thyroid tumors, although it remains unknown whether this risk extends to humans.

Fourth... the cost. We are talking about an expensive medication that requires continuous use. Studies show that when a person stops taking it, the weight tends to return. As for the long term mental health effects after discontinuation, science does not yet have an answer.

And fifth, perhaps the most subtle point... clinical trials by Novo Nordisk and Eli Lilly systematically excluded patients with a history of severe depression, schizophrenia, bipolar disorder or suicide attempts. This means that precisely the people who could benefit most from a psychiatric effect... or be most harmed by one... were not rigorously tested. A randomized clinical trial has already tested oral semaglutide in patients with major depression and cognitive impairment. The drug proved safe in that population and improved some measures of global cognition, but it did not reach the primary endpoint of improving executive function. It is a start, but far from definitive proof.

What to do with this information

This is one of those moments when science opens a door without yet illuminating what lies on the other side. What do we know, and what can we do right now?

If you already use semaglutide for diabetes or obesity and have noticed an improvement in your mood... it is not a coincidence, it is not a placebo effect and it is not in your head. The data suggest that something real is happening. Talk to your doctor about it. Recording these changes helps science move forward.

If you do not use the medication and are thinking about asking for a prescription because of mental health... slow down. There is no regulatory approval for that use. Novo Nordisk has a phase three program for semaglutide in major depression underway, with data expected by the end of two thousand and twenty six. Until then, using Ozempic as an antidepressant is driving ahead of your headlights.

If you are a healthcare professional... the message from the Swedish study is clear. Anyone prescribing semaglutide for diabetes or obesity should be monitoring mental health. And anyone treating mental health should be asking whether the patient is using a GLP one agonist. Today, general practice prescribes on one side and psychiatry follows up on the other, often without talking to each other. That gap between the two specialties is exactly where adverse signals get lost.

For investors and those following the pharmaceutical market... the race has already begun. If semaglutide or its competitors demonstrate psychiatric efficacy in controlled clinical trials, we are talking about a market that could multiply several times over. Depression is the leading cause of disability worldwide. But beware of premature euphoria. The road between a promising observational study and regulatory approval is long, expensive and full of twists.

And for all of us... this study reminds us of something that medicine has been gradually rediscovering. Body and mind are not separate departments. A gut hormone interferes with dopamine in the brain. Weight affects mood. Mood affects weight. The same molecule that controls blood sugar may be recalibrating the system that makes us feel pleasure and motivation.

Semaglutide may not be the drug of the moment. It may be the beginning of a new way of understanding how metabolic health and mental health are connected. And that, regardless of what happens with Ozempic, is already a discovery that changes the conversation.